At XBiotech we are rethinking the way medicines are discovered and commercialized—from pioneering ways to create safer drugs that harness our natural immunity to disease, to developing technology that enables rapid transition from discovery to large-scale manufacturing. At XBiotech we believe there is vast potential for next generation antibody therapies derived from natural immunity to disease. We also believe that to unlock the vast potential of natural immunity to treat escalating global demand for medicine, more cost effective commercialization strategies are needed. To this end, we have developed production technology that is easier to scale-up and more flexible to respond to the rapidly evolving market opportunities, much of which will be created by new safer therapies themselves. At XBiotech we continue to refine and develop systems and strategies to advance our capability to identify antibody therapies from healthy human immunity and avail these to patients in need. In 2015, we believe our innovation in technology and in the clinic enables us to bring our new discoveries to patients faster and with leaner infrastructure than any other biopharmaceutical developer in the industry.